Sofosbuvir and Velpatasvir Tablets(Epclusa)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Epclusa(Sofosbuvir and Velpatasvir Tablets) Instructions:Uses,Dosage, Side Effects
EPCLUSA is a fixed-dose combination prescription drug containing two active ingredients, sofosbuvir and velpatasvir. It is a direct-acting antiviral medication formulated as tablets or oral pellets, designed to treat chronic hepatitis C virus (HCV) infection in adults and pediatric patients aged 3 years and older. This medication works by targeting and inhibiting specific proteins essential for the replication of the hepatitis C virus within the body.
Generic name
Sofosbuvir and Velpatasvir Tablets(Epclusa)
English name
Sofosbuvir and Velpatasvir Tablets
Alternative Names
Epclusa
Indications
Indicated for the treatment of adult and pediatric patients (3 years of age and older) with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection:
Without cirrhosis or with compensated cirrhosis (Child-Pugh A).
With decompensated cirrhosis (Child-Pugh B or C) for use in combination with ribavirin.
Therapeutic Target
the HCV NS5B RNA-dependent RNA polymerase (sofosbuvir) and the HCV NS5A protein (velpatasvir)
Active Ingredients
sofosbuvir and velpatasvir
specifications
400mg/100mg * 28 tablets/box
Dosage and Administration
Adults: One 400 mg/100 mg tablet orally, once daily, with or without food.
Contact Us
Mailbox:Info@Lucius.La
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved